Skip to main content
. 2009 Aug 31;106(37):15927–15931. doi: 10.1073/pnas.0907324106

Table 2.

ARs antagonists generally stabilize GABAA receptors microtransplanted to oocytes from dysplastic neocortices

Drug treatment (dose) Tested oocytes (frogs) [patients] IGABA, %, before treatment (n) IGABA, %, after treatment P
PFCD
    ANR82 (100 nM) [A2A antagonist] 41 (6) [6–9] 62.1 ± 4.8 (6) 47.5 ± 2.4 <0.01
45.8 ± 2.1 (27) 60.9 ± 1.5 <0.001
    ANR94 (100 nM) [A2A antagonist] 20 (4) [6 and 7] 46.5 ± 2.0 (10) 55.5 ± 2.4 <0.001
    ANR152 (100 nM) [A2A & A1 antagonist] 12 (2) [6] 51.7 ± 2.8 (8) 69.0 ± 2.4 <0.001
    ANR235 (100 nM) [A3 antagonist] 24 (4) [6–8] 48.5 ± 3.3 (24)* 50.7 ± 2.9* >0.5
AFCD
    ANR82 (100 nM) [A2A antagonist] 22 (3) [10 and 11] 75 (1) 66.7 -
51.6 ± 1.9 (18) 69.4 ± 1.7 <0.001
    ANR94 (100 nM) [A2A antagonist] 23 (4) [10–12] 56.2 ± 2.2 (13) 72.6 ± 2.8 <0.001
    ANR152 (100 nM) [A1 and A2A antagonist] 12 (2) [10 and 12] 51.7 ± 2.0 (9) 64.5 ± 2.7 <0.001
    ANR152 (10 nM) [A2A antagonist] 11 (2) [12] 59.7 ± 2.3 (9) 67.2 ± 2.0 <0.001
    Mix DPCPX (30 nM) [A1 antagonist] 10 (2) [10] 54.3 ± 4 (7) 68.5 ± 4 <0.001
    ANR152 (10 nM) [A2A antagonist] 61.2 + 4 (3) 58.8 ± 4* >0.5
    DPCPX (30 nM) [A1 antagonist] 3 (1) [10] 57.1 ± 1.3 (3) 57.2 ± 0.7 >.5
    ANR235 (100 nM) [A3 antagonist] 8 (2) [10 and 11] 42.6 ± 5.7 (8)* 34.6 ± 3.5* >.5

n, number of oocytes responsive to AR antagonists. Set of cells in which rundown increases and n are in bold. IGABA (%) values represent the sixth IGABA amplitude normalized to the first of the rundown protocol.

*, Not significantly different.